Pilot Study of a Raltegravir Based NRTI Sparing Regimen
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
This pilot study will provide data on the safety and efficacy of the combination of
Raltegravir (RAL) 400mg BID + Atazanavir (ATV) 300 mg BID in Antiretroviral (ARV)-experienced
subjects that have a suppressed HIV viral load on a Ritonavir (RTV) boosted Protease
Inhibitor (PI) based regimen who are then switched to a regimen of RAL 400mg BID +ATV 300mg
BID.